The overall objectives of this research are to develop methods (1) for estimating vaccine efficacy and effectiveness in the field and (2) for characterizing complex and long-term properties of vaccination in individuals and populations.
The specific aims are 1. To continue development of study designs and methods of analysis for using validation samples to correct for misclassified or partially observed outcomes and missing data in vaccine studies. The goal is improved estimates of protective vaccine efficacy, VES, and vaccine efficacy for infectiousness, VEI, as well as designs for efficient, cost-effective studies. 2. To continue development of cluster-randomized designs to evaluate indirect, total, and overall effectiveness of vaccination strategies. This includes methods for optimal spatial randomization constraints. A new stepped wedge study using longitudinal and cross-sectional carriage studies as baseline data will be developed. The new mini-community design to evaluate indirect effects will be developed in which the cluster is a household or other small transmission unit. 3. To develop methods for joint estimation of the protective effects of vaccination, VES and vaccine efficacy for infectiousness, VEI from households embedded within clusters in a cluster-randomized trial. 4. To develop methods to evaluate immunological correlates of protection that combine models accounting for exposure to infection with approaches delineating different degrees of confidence about the correlate. 5. To continue to explore interpretation of the protective effects of vaccination, VES, when combining results across studies in different populations, taking into account different levels of baseline transmission and pre-existing immunity. This includes developing methods for evaluating vaccine efficacy when a vaccine puts evolutionary pressure on the composition of the population of circulating strains. Statistical approaches to be developed include likelihood inference, Bayesian methods, semiparametric methods, hierarchical models, and survival methods. These methods will be motivated by the design and analysis of studies of influenza, pneumococcal, meningococcal A, rotavirus, and malaria transmission blocking vaccines.

Public Health Relevance

The overall objectives of this research are to develop statistical and epidemiologic methods (1) for estimating vaccine efficacy and effectiveness in the field and (2) for characterizing complex and long-term properties of vaccination in individuals and populations. Our research is motivated by influenza, meningococcal A, pneumococcal, rotavirus, and malaria vaccine field studies on several continents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI032042-21
Application #
8663159
Study Section
Biostatistical Methods and Research Design Study Section (BMRD)
Program Officer
Gezmu, Misrak
Project Start
1992-01-01
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
21
Fiscal Year
2014
Total Cost
$507,032
Indirect Cost
$213,695
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Feldstein, Leora R; Rowhani-Rahbar, Ali; Staples, J Erin et al. (2017) Persistent Arthralgia Associated with Chikungunya Virus Outbreak, US Virgin Islands, December 2014-February 2016. Emerg Infect Dis 23:673-676
Schwartz, Lauren M; Halloran, M Elizabeth; Rowhani-Rahbar, Ali et al. (2017) Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. Vaccine 35:184-190
Halloran, M Elizabeth; Auranen, Kari; Baird, Sarah et al. (2017) Simulations for designing and interpreting intervention trials in infectious diseases. BMC Med 15:223
Henao-Restrepo, Ana Maria; Camacho, Anton; Longini, Ira M et al. (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 389:505-518
Zaman, K; Sack, David A; Neuzil, Kathleen M et al. (2017) Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Med 14:e1002282
Dean, Natalie E; Halloran, M Elizabeth; Yang, Yang et al. (2016) Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection. Clin Infect Dis 62:1277-1286
Merler, Stefano; Ajelli, Marco; Fumanelli, Laura et al. (2016) Containing Ebola at the Source with Ring Vaccination. PLoS Negl Trop Dis 10:e0005093
Flasche, Stefan; Jit, Mark; Rodríguez-Barraquer, Isabel et al. (2016) The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Med 13:e1002181
Feldstein, Leora R; Ellis, Esther M; Rowhani-Rahbar, Ali et al. (2016) The First Reported Outbreak of Chikungunya in the U.S. Virgin Islands, 2014-2015. Am J Trop Med Hyg 95:885-889
Halloran, M Elizabeth; Hudgens, Michael G (2016) Dependent Happenings: A Recent Methodological Review. Curr Epidemiol Rep 3:297-305

Showing the most recent 10 out of 38 publications